The future of molecular diagnostics is becoming increasingly spatial, and in situ hybridization (ISH) technologies are playing a pivotal role in this transformation. As healthcare and life sciences move toward precision medicine, researchers and clinicians are relying more heavily on advanced molecular profiling tools that reveal not only what genes are expressed but also where they are expressed within tissues.
Driven by continuous technological innovation and expanding clinical applications, the global in situ hybridization (ISH) market is projected to grow from USD 1.64 billion in 2025 to USD 2.35 billion by 2030, registering a CAGR of 7.4% during the forecast period. From cancer diagnostics to neuroscience research, ISH is rapidly evolving into a cornerstone technology for understanding complex biological systems.
The Rise of Spatial Biology and Precision Medicine
One of the biggest forces shaping the ISH market is the growing demand for spatial transcriptomics. Unlike conventional genomic techniques that analyze tissues in bulk, spatial biology technologies preserve tissue architecture, allowing researchers to map gene expression directly within its biological context.
This capability is transforming research in oncology, neuroscience, and immunology. Scientists can now identify cellular interactions, disease-driving pathways, and therapeutic targets with unprecedented precision. As a result, ISH technologies are becoming essential tools for studying tumor microenvironments, neurodegenerative disorders, and immune responses.
At the same time, the rise of precision medicine is creating new opportunities for ISH-based diagnostics. Healthcare providers increasingly require patient-specific molecular insights to guide treatment decisions, making ISH assays valuable for detecting genetic biomarkers and supporting personalized therapeutic strategies.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829
Automation and Multiplexing Drive the Next Generation of ISH
The modern ISH landscape is being reshaped by automation and multiplexing technologies that improve assay sensitivity, specificity, and laboratory efficiency.
Researchers are moving beyond single-target analysis toward highly multiplexed workflows capable of simultaneously detecting multiple RNA and protein biomarkers within a single tissue sample. These advancements provide richer biological insights while reducing turnaround times and operational complexity.
A key example emerged in 2025 when Leica Biosystems collaborated with Bio-Techne’s Advanced Cell Diagnostics (ACD) division to automate RNAscope Multiomic LS assays on the BOND RX platform. This innovation enables simultaneous RNA and protein detection without protease treatment, enhancing both spatial resolution and laboratory productivity.
Similarly, Leica Biosystems expanded its capabilities through a partnership with Molecular Instruments, integrating HCR Pro RNA-ISH technology into its BOND platforms. The result is highly sensitive multiplex detection with support for both fluorescence and brightfield imaging—an important advancement for translational and clinical research environments.
Industry Leaders Strengthen Their Market Positions
The global ISH market remains highly consolidated, with several established players leading innovation through product development, strategic partnerships, and regulatory achievements.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=212028829
Roche Advances Clinical ISH Applications
F. Hoffmann-La Roche Ltd continues to strengthen its leadership position through its integrated diagnostics ecosystem and commitment to precision oncology.
A major milestone came in January 2025 when Roche received FDA 510(k) clearance for its VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay. This breakthrough became the first FDA-cleared ISH test capable of detecting the full spectrum of B-cell lymphoma subtypes with enhanced sensitivity. The approval represents an important step toward broader clinical adoption of advanced ISH technologies and highlights the growing regulatory acceptance of molecular pathology solutions.
Roche’s ongoing investments in automation platforms such as the BenchMark ULTRA PLUS system further reinforce its ability to support high-throughput pathology laboratories while improving workflow efficiency and diagnostic accuracy.
Abbott Expands Diagnostic Excellence
Abbott remains a key player in the ISH market through its widely recognized VYSIS portfolio, which serves applications ranging from oncology diagnostics to cytogenetics.
Products such as the UroVysion Bladder Cancer Kit and VYSIS CLL FISH Probe Kit have established Abbott as a trusted provider of fluorescence in situ hybridization (FISH) solutions worldwide. Supported by a strong global distribution network and extensive technical resources, the company continues to play a vital role in advancing molecular diagnostics and personalized medicine.
Bio-Techne Fuels Growth in RNA-ISH
Bio-Techne has emerged as a dominant force in RNA-based ISH applications. In February 2025, the company expanded its RNAscope portfolio to include more than 70,000 unique probes covering over 450 species.
This remarkable expansion reflects increasing demand for spatial transcriptomics and high-plex tissue analysis across oncology, neuroscience, and immunology research. By offering solutions compatible with both manual and automated workflows, Bio-Techne is helping laboratories transition seamlessly from exploratory research to clinical assay development.
What Lies Ahead for the ISH Market?
The future of the in situ hybridization market will be defined by three major trends: automation, multiplexing, and integrated multiomic analysis. As researchers seek deeper biological insights, technologies capable of simultaneously analyzing RNA, proteins, and spatial information will become increasingly valuable.
With strong investments from industry leaders such as Roche, Abbott, Danaher, Bio-Techne, and Thermo Fisher Scientific, the market is well-positioned for sustained growth. Meanwhile, the growing role of ISH in precision medicine, cancer diagnostics, infectious disease research, and neuroscience will continue to expand its clinical and commercial significance.
As spatial biology moves from research laboratories into mainstream healthcare, in situ hybridization is emerging as one of the most influential technologies driving the next generation of molecular diagnostics and personalized medicine.
For more information, Inquire Now!
